Michael Shafique

1.1k total citations
35 papers, 412 citations indexed

About

Michael Shafique is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Michael Shafique has authored 35 papers receiving a total of 412 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 18 papers in Pulmonary and Respiratory Medicine and 10 papers in Molecular Biology. Recurrent topics in Michael Shafique's work include Cancer Immunotherapy and Biomarkers (18 papers), Lung Cancer Treatments and Mutations (16 papers) and Lung Cancer Research Studies (9 papers). Michael Shafique is often cited by papers focused on Cancer Immunotherapy and Biomarkers (18 papers), Lung Cancer Treatments and Mutations (16 papers) and Lung Cancer Research Studies (9 papers). Michael Shafique collaborates with scholars based in United States, Germany and Japan. Michael Shafique's co-authors include Andreas Saltos, Alberto Chiappori, Sonam Puri, Tawee Tanvetyanon, Jhanelle E. Gray, Scott Antonia, Ben Creelan, Eric B. Haura, Dung‐Tsa Chen and James J. Saller and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Clinical Cancer Research.

In The Last Decade

Michael Shafique

30 papers receiving 409 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Shafique United States 9 287 167 120 86 71 35 412
María González Cao Spain 12 207 0.7× 144 0.9× 107 0.9× 79 0.9× 28 0.4× 38 336
Bożena Cybulska-Stopa Poland 11 246 0.9× 102 0.6× 73 0.6× 81 0.9× 36 0.5× 58 330
Carina Hage Switzerland 6 135 0.5× 171 1.0× 71 0.6× 113 1.3× 36 0.5× 7 342
Nooshin Hashemi Sadraei United States 10 199 0.7× 130 0.8× 66 0.6× 60 0.7× 63 0.9× 30 321
Ana T. Nunes United States 11 275 1.0× 120 0.7× 70 0.6× 81 0.9× 55 0.8× 19 455
Marion Jacquin France 8 161 0.6× 156 0.9× 56 0.5× 128 1.5× 33 0.5× 16 340
Arsène‐Bienvenu Loembé United Kingdom 9 196 0.7× 168 1.0× 100 0.8× 42 0.5× 32 0.5× 15 377
Francesca Sparano Italy 9 219 0.8× 113 0.7× 103 0.9× 78 0.9× 22 0.3× 19 369
Vui Pham United States 5 275 1.0× 223 1.3× 75 0.6× 159 1.8× 23 0.3× 5 447
Carmelo Lupo Italy 11 176 0.6× 150 0.9× 137 1.1× 47 0.5× 32 0.5× 25 390

Countries citing papers authored by Michael Shafique

Since Specialization
Citations

This map shows the geographic impact of Michael Shafique's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Shafique with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Shafique more than expected).

Fields of papers citing papers by Michael Shafique

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Shafique. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Shafique. The network helps show where Michael Shafique may publish in the future.

Co-authorship network of co-authors of Michael Shafique

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Shafique. A scholar is included among the top collaborators of Michael Shafique based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Shafique. Michael Shafique is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ahmed, Kamran A., Allison Quick, Hye Sook Chon, et al.. (2025). Atezolizumab and Stereotactic Body Radiation in Metastatic, Recurrent, or Persistent Cervical Cancer: Results From a Phase 2 Multi-Institutional Study. International Journal of Radiation Oncology*Biology*Physics.
2.
Perez, Bradford A., Raid Aljumaily, Thomas U. Marron, et al.. (2024). Phase I study of peposertib and avelumab with or without palliative radiotherapy in patients with advanced solid tumors. ESMO Open. 9(2). 102217–102217. 10 indexed citations
3.
Pellini, Bruna, Jiannong Li, Michael J. Schell, et al.. (2024). A phase II trial of AZD1775 plus carboplatin-paclitaxel in squamous cell lung cancer (SqCLC).. Journal of Clinical Oncology. 42(16_suppl). 8545–8545. 1 indexed citations
4.
Saltos, Andreas, Tawee Tanvetyanon, Ben Creelan, et al.. (2023). Phase II randomized trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC): Final results.. Journal of Clinical Oncology. 41(16_suppl). 9125–9125. 2 indexed citations
5.
Thapa, Ram, Michael Shafique, Andreas Saltos, et al.. (2023). Osimertinib vs. afatinib as first-line treatment for patients with metastatic non-small cell lung cancer with an EGFR exon 19 deletion or exon 21 L858R mutation. Journal of Thoracic Disease. 15(11). 6115–6125. 4 indexed citations
6.
Saltos, Andreas, Ben Creelan, Tawee Tanvetyanon, et al.. (2023). A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring activating KRAS or EGFR mutations. Lung Cancer. 183. 107313–107313. 3 indexed citations
7.
Meng, Lingbin, Biwei Cao, Rui Ji, et al.. (2023). Enhanced Efficacy of Chemotherapy by Addition of Immune Checkpoint Inhibitors in Stage IV Large Cell Neuroendocrine Carcinoma of the Lung: A Real-World Analysis. Journal of Cancer. 14(17). 3169–3175. 3 indexed citations
8.
Puri, Sonam, Tawee Tanvetyanon, Ben Creelan, et al.. (2023). The final analysis of a phase I/II study of nivolumab, ipilimumab combined with nintedanib in advanced non-small cell lung cancer.. Journal of Clinical Oncology. 41(16_suppl). 9102–9102. 1 indexed citations
9.
Shafique, Michael, et al.. (2022). Rapid Improvement Following Receipt of Infliximab in Steroid-refractory Durvalumab-Associated Grade 3 Pneumonitis. Cureus. 14(2). e22295–e22295. 3 indexed citations
10.
Boyer, Michael, Sandip H. Patel, Thomas U. Marron, et al.. (2021). 456 A phase 1b/2 umbrella study of anti-PD-1 sasanlimab in combination with other therapies for patients with stage IIIB/IV non-small cell lung cancer (NSCLC): The LANDSCAPE 1011 trial in progress. Regular and Young Investigator Award Abstracts. A484–A484. 1 indexed citations
11.
Saltos, Andreas, Michael Shafique, & Alberto Chiappori. (2020). Update on the Biology, Management, and Treatment of Small Cell Lung Cancer (SCLC). Frontiers in Oncology. 10. 1074–1074. 103 indexed citations
12.
Puri, Sonam & Michael Shafique. (2020). Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies. Drugs in Context. 9. 1–11. 35 indexed citations
13.
Gray, Jhanelle E., Andreas Saltos, Tawee Tanvetyanon, et al.. (2019). Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer. Clinical Cancer Research. 25(22). 6623–6632. 104 indexed citations
14.
Bendell, Johanna C., et al.. (2019). Phase 1, open-label, dose-escalation study of M3814 + avelumab ± radiotherapy (RT) in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 37(15_suppl). TPS3169–TPS3169. 6 indexed citations
15.
Franke, Aaron J, Viswam S. Nair, Michael Shafique, & Sepideh Mokhtari. (2019). P2.14-69 Lorlatinib Rescue Therapy for Life Threatening CNS Disease in Crizotinib-Resistant ROS1-Positive Non–Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 14(10). S858–S859.
16.
Shafique, Michael, Lary A. Robinson, & Scott Antonia. (2018). Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer. Cancer Management and Research. Volume 10. 931–940. 12 indexed citations
17.
Puri, Sonam, Michael Shafique, & Jhanelle E. Gray. (2018). Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer. Current Treatment Options in Oncology. 19(8). 39–39. 17 indexed citations
18.
Shafique, Michael, Marie Catherine Lee, & Hyo S. Han. (2017). Treatment of the Pregnant Patient with Breast Cancer. Southern Medical Journal. 110(10). 627–631.
19.
Turza, Kristin C., Michael Shafique, Peter I. Lobo, et al.. (2014). Infectious Complications in Living-Donor Kidney Transplant Recipients Undergoing Multi-Modal Desensitization. Surgical Infections. 15(3). 182–186. 1 indexed citations
20.
Kanda, Junya, Gwynn D. Long, Cristina Gasparetto, et al.. (2013). Reduced-Intensity Allogeneic Transplantation Using Alemtuzumab from HLA-Matched Related, Unrelated, or Haploidentical Related Donors for Patients with Hematologic Malignancies. Biology of Blood and Marrow Transplantation. 20(2). 257–263. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by María González Cao Breakdown of academic impact, for papers by Bożena Cybulska-Stopa Breakdown of academic impact, for papers by Carina Hage Breakdown of academic impact, for papers by Nooshin Hashemi Sadraei Breakdown of academic impact, for papers by Ana T. Nunes Breakdown of academic impact, for papers by Marion Jacquin Breakdown of academic impact, for papers by Arsène‐Bienvenu Loembé Breakdown of academic impact, for papers by Francesca Sparano Breakdown of academic impact, for papers by Vui Pham Breakdown of academic impact, for papers by Carmelo Lupo
Rankless by CCL
2026